Summary: Celltrion, Inc.

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Highlights: Celltrion, Inc.

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: Celltrion, Inc.

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 91.41 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • The company is highly valued given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.

Ratings Chart: Celltrion, Inc.

Source: Surperformance

ESG chart: Celltrion, Inc.

Source: MSCI

Add to a list
Fundamentals Valuation Revisions of Fundamental Estimates Capi.($)
26.18B
48.01B
36.45B
15.76B
15.43B
11.05B
10.99B
8.66B
Average 21.57B
Weighted average by Cap.
See all sector ratings
Investor
Trader
ESG MSCI
B

Financials

Sales growth
EPS Growth
Profitability
Net margin
Financial Health

Valuation

P/E ratio
EV/REVENUE
EV/EBITDA
PBR
Yield

Revisions

1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision

Business Predictability

Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions

ESG

Environment
Social
Governance
Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
Sharia compliant
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes